Active Cycle Of Breathing Technique And Pursed Lip Breathing in Moderate to Severe COPD Patients

July 28, 2026 updated by: University of Lahore

Purpose of the Study Chronic Obstructive Pulmonary Disease (COPD) is a progressive, long-term lung condition that limits airflow and makes breathing difficult. People with COPD frequently experience shortness of breath, chronic coughing, and mucus buildup, which can severely impact their daily activities and overall quality of life. While medications are commonly used, non drug therapies like specialized breathing exercises are becoming vital tools to help relieve symptoms.

The purpose of this study is to compare two popular breathing techniques the Active Cycle of Breathing Technique (ACBT) and Pursed-Lip Breathing (PLB) to determine which method is more effective at improving lung function, reducing breathlessness, and enhancing the overall quality of life for individuals living with moderate to severe COPD.

Study Plan and Methods

This study is a randomized controlled trial lasting approximately 8 to 10 months. A total of 40 eligible participants (both men and women aged 40 to 55) will be recruited and randomly split into two equal groups:

Group A (Active Cycle Breathing): Participants will practice ACBT, which combines relaxed breathing, deep chest-expanding breaths, and a specialized coughing technique ("huffing") to clear trapped mucus from the lungs Group B (Pursed-Lip Breathing): Participants will practice PLB, a technique where they inhale slowly through the nose and exhale gently through puckered lips (like blowing out a candle) to slow down breathing and improve ventilation Both groups will receive their assigned breathing exercise alongside standard medical care and a baseline postural drainage treatment. Exercises will be performed in 15-to-20-minute sessions, twice a day, for a total of 8 weeks.

Expected Outcomes Researchers will evaluate participants before and after the 8-week program using standard lung function tests (spirometry), breathlessness questionnaires, and quality-of-life assessments. The study expects both techniques to offer relief, but aims to identify if one method provides superior evidence-based benefits. The ultimate goal is to help physical therapists and doctors design more effective, personalized pulmonary rehabilitation programs for COPD patients.

Study Overview

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab Province
      • Lahore, Punjab Province, Pakistan
        • Dr.Sidra Faisal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both genders.
  • Subjects with the 40-55 age years.
  • Diagnosed with COPD
  • Subjects who are on regular treatment
  • Subjects who are conscious and cooperative
  • Subjects who can understand and follow instruction

Exclusion Criteria:

  • • Patients with recent abdominal, and thoracic surgery.

    • Patients with any Disability; Physical or Mental.
    • Patients with unstable angina, advanced congestive heart failure, or severe pulmonary hypertension, because altered intrathoracic pressures during forced expirations strain the heart.
    • Patients with advanced kyphoscoliosis or severe pectus excavatum, as baseline structural restrictions prevent optimal diaphragmatic excursion and chest wall expansion.
    • Patients presenting with severe resting hypoxemia or highly volatile blood oxygen values at baseline that require continuous emergency clinical monitoring.
    • Patients who have experienced a sudden worsening or an acute clinical crash within the past 4 weeks, as the forced expiratory components (such as huffing) involved in active airway clearance can severely exacerbate active bronchospasms.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A: Active Cycle of Breathing Technique (ACBT)

For Arm 1 (Group A), enter this text into the description field:

Active Cycle of Breathing Technique (ACBT) group. Participants in this arm will perform the Active Cycle of Breathing Technique, which combines three phases: breathing control (relaxed breathing), thoracic expansion (deep breaths), and the forced expiratory technique ("huffing") to mobilize and clear mucus from the lungs. The intervention will be administered in 2 sessions per day for a total duration of 8 weeks. Each session will last approximately 15 to 20 minutes. Participants will also receive standard COPD medical care and medication, alongside standard baseline postural drainage.

The intervention consists of the Active Cycle of Breathing Technique (ACBT), a flexible regimen of breathing exercises designed to clear excess secretions from the lungs. It will be performed in 3 distinct phases: 1) Breathing Control (relaxed, gentle breathing to calm the airways), 2) Thoracic Expansion (deep, controlled breaths to expand the chest and loosen mucus), and 3) Forced Expiratory Technique/FET (using "huffing" to mobilize and clear mucus). Participants will perform 2 sessions a day, lasting 15-20 minutes per session, for a total of 8 weeks. All sessions will be conducted under standard baseline postural drainage alongside standard medical care.
Experimental: Group B: Pursed Lip Breathing Technique (PLB)
Pursed Lip Breathing (PLB) group. Participants in this arm will perform Pursed Lip Breathing, a technique where they slowly inhale through the nose for 2 counts and gently exhale through puckered lips for 4 or more counts to slow breathing and improve ventilation. The intervention will be administered in 2 sessions per day for a total duration of 8 weeks. Each session will last approximately 15 to 20 minutes. Participants will also receive standard COPD medical care and medication, alongside standard baseline postural drainage.
The intervention consists of the Pursed Lip Breathing (PLB) technique, a breathing exercise aimed at reducing breathlessness and improving ventilation efficiency. Participants are trained to slowly inhale through the nose for 2 counts (allowing the belly to expand) and gently exhale through puckered lips for 4 or more counts without forcing the air out. Participants will perform 2 sessions a day, lasting 15-20 minutes per session, for a total of 8 weeks. All sessions will be conducted under standard baseline postural drainage alongside standard medical care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
orced Expiratory Volume in 1 second (FEV1)
Time Frame: Baseline and post-intervention at 8 weeks
Baseline and post-intervention at 8 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Pulmonary Function Test (FEV1/FVC Ratio)
Time Frame: Baseline and post-intervention at 8 weeks
Baseline and post-intervention at 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 11, 2025

Primary Completion (Actual)

February 20, 2026

Study Completion (Actual)

June 30, 2026

Study Registration Dates

First Submitted

July 14, 2026

First Submitted That Met QC Criteria

July 28, 2026

First Posted (Actual)

August 3, 2026

Study Record Updates

Last Update Posted (Actual)

August 3, 2026

Last Update Submitted That Met QC Criteria

July 28, 2026

Last Verified

June 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe